Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Health Canada's Johnson: Generic Semaglutide Review More Complex
Health Canada spokesperson Mark Johnson explains why generic semaglutide submissions face a more involved review than typical generics, citing synthetic peptide complexity.
Felix Tells Existing Patients: Auto-Switch to Lower Generic Price
Felix says existing semaglutide patients need take no action — their next fill will be charged at the new lower price as generic competition arrives in Canada.
Obesity Canada's Patton, McGill's Dasgupta Weigh Generic Approvals
Obesity Canada advocacy director Ian Patton calls generic semaglutide approval exciting, while McGill's Dr. Kaberi Dasgupta urges caution on over-reliance.
Canada Generics Mark Start of Semaglutide International Revenue Decline: BMO
BMO Capital Markets says Canada's two approved generic semaglutides likely mark the start of a decline in Novo Nordisk's international semaglutide revenue.
Wegovy Titration Costs $2,160-$2,280 Before Maintenance Dose in Canada
Wegovy's 16-week titration to the 2.4 mg maintenance dose costs Canadian patients $2,160-$2,280 before they reach full-dose therapy, with no provincial coverage.
Health Canada 2026-27 Plan Ties Generic Approvals to Reimbursement
Health Canada's 2026-27 Departmental Plan names pharmaceutical affordability a key priority, aligning regulatory approval with reimbursement recommendations.
CBC Correction: Novo's Semaglutide Regulatory Exclusivity Ended January
CBC corrected its generic Ozempic report to clarify Novo Nordisk's regulatory exclusivity ended in January 2026, not the patent, which expired earlier.
Novo EVP Larsen Calls Savings Card 'Leading Tactic' in Canada
Novo Nordisk EVP Emil Kongshoj Larsen told investors the company's savings card is its 'leading tactic' against Canadian generic semaglutide competitors.
Pharmacy Cash Price Gaps: Costco Undercuts Rexall by Up to $90
A 2026 price guide shows Canadian pharmacies vary by $50–$100 monthly on semaglutide cash prices, with Costco lowest and Rexall highest among major chains.
CMA: Ontario Lists Ozempic as Limited Use; Alberta Requires Step Therapy
CMA explainer details how Ontario lists Ozempic as Limited Use and Alberta treats it as step therapy, while generic semaglutide substitution rules take shape.
Novo Nordisk Eyes Third Generic as 65% Price-Cut Trigger Looms
Novo Nordisk executive Emil Kongshøj Larsen says a third generic semaglutide entry in Canada will trigger a mandated 65% cut to Novo's list price.
Generic Semaglutide Hits Tier 2 Pricing: ~$114 Per 4-Week Supply
With two generic semaglutide approvals in Canada, pCPA tier rules cap the public-plan price at roughly $114 per four-week supply, skipping Tier 1 entirely.
Health Canada Advisory: Counterfeit GLP-1 Products Found in Canada
Health Canada warns consumers about unauthorized and counterfeit GLP-1 products sold by retailers and online, and is working with CBSA to block shipments.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to decline even as a semaglutide generic arrives mid-2026, citing broader uses.
CDA Pegs Mounjaro Public Coverage at $1.97B Over Three Years
Canada's Drug Agency estimates public plans would spend $1.97 billion on Mounjaro over three years, about $820 million more than current comparable drug spending.
Health Canada: Many Generics Run 45-90% Below Brand Prices
Health Canada says many generic medications cost 45 to 90 per cent less than brand-name versions, a benchmark now in focus after two semaglutide approvals.
BMO Analyst: Canada Is 'Test Case' for Generic GLP-1 Competition
BMO Capital Markets analyst Evan Seigerman says investors will watch Canada closely to see whether generic semaglutide can compete with branded peptides.
Gerstein: GLP-1s Are 'Powerful Drugs,' Not Supplements
Hamilton diabetes researcher Dr. Hertzel Gerstein cautions Canadians that semaglutide is a powerful drug, not a supplement, as the second generic clears Health Canada.
Sockalingam: Under 20% of Private Plans Cover Obesity Drugs
Obesity Canada's Dr. Sanjeev Sockalingam says fewer than 20% of Canadians with private drug plans can access approved obesity medications, citing $27.6B in 2023 costs.
Second Generic Semaglutide Cleared; 7 Submissions Still Pending
Health Canada authorized Apotex's generic semaglutide May 1, 2026, the second G7-first approval, with seven more generic submissions still under review.
Health Canada Queue: 7 Semaglutide Generics Await Decisions
After authorizing a second generic semaglutide on May 1, Health Canada says seven more submissions remain under review with decisions due in coming weeks.
Novo Nordisk Sees 'Low Single-Digit' Hit from Canadian Generics
Novo Nordisk executive Emil Kongshøj Larsen told analysts the company expects only a low single-digit impact from generic semaglutide entering Canada.
Experts Welcome Generic Semaglutide, Urge Caution on Reliance
McGill's Dr. Kaberi Dasgupta and Obesity Canada's Ian Patton react to Health Canada's G7-first generic semaglutide approvals, citing equity gains and public-health risks.
Obesity Canada: Generic Semaglutide Approval Should Reshape Coverage
Obesity Canada says Health Canada's generic semaglutide approvals should prompt governments and insurers to revisit coverage, citing under-20% private plan access.
Health Canada Confirms G7-First Status After Apotex Generic Nod
Health Canada confirms G7-first generic semaglutide status after authorizing Apotex's version, with seven additional submissions still under active review.
Apotex Generic Semaglutide to Reach Canadian Pharmacies in Weeks
Apotex says its newly approved generic semaglutide injection should be available at Canadian pharmacies within weeks, the company's communications VP confirmed.
Generic Semaglutide Pipeline: 7 Submissions Still Under Review
Health Canada confirms seven generic semaglutide submissions remain under review after the second approval on May 1, 2026, with more decisions expected.
Ozempic Topped Canadian Drug Sales at $2.9B in 2025: IQVIA
Ozempic was Canada's best-selling drug in 2025 with $2.9B in sales, more than triple the next-ranked medication, IQVIA data shows as generics arrive.
Apotex Won't Manufacture Generic Semaglutide in Canada
Apotex president Martin Arès confirms generic semaglutide pens won't be made at Canadian facilities, citing specialized manufacturing requirements.
Apotex Wins Health Canada Nod for 2nd Generic Semaglutide
Health Canada authorized Apotex's generic semaglutide injection on May 1, 2026, the second generic of Ozempic approved in the G7, with 7 more submissions in review.
Health Canada Reviewing 8 More Generic Semaglutide Submissions
Health Canada says decisions on 8 remaining generic semaglutide submissions are expected in coming weeks and months after Dr. Reddy's first approval.
Provincial Coverage of Generic Semaglutide Uncertain After G7-First Approval
Canada became the first G7 country to approve generic semaglutide, but provincial drug plan coverage remains uncertain and varies by province.
Wegovy Pricing Snapshot: Retail $400–$570, Generic Seen Summer 2026
Teletest pegs Wegovy at $400–$570/month in Canada with a generic projected for summer 2026 at $40–$160, while employer coverage data shows narrow access.
Generic Semaglutide Starts at 75% of List Price Under pCPA Rules
Canada's generic pricing framework starts Dr. Reddy's semaglutide at 75% of Ozempic's $228 four-week list price, dropping to 35% with three approved makers.
Generic Semaglutide Filing Dates: How Long Apps Have Waited
Health Canada's generic submissions tracker and Globe and Mail reporting reveal generic semaglutide applications dating back to February 2024 still under review.
Felix Publishes Generic Semaglutide Price Tiers: $112-$240 Per Pen
Telehealth provider Felix outlines a tiered generic semaglutide pricing forecast ranging from $240 down to $112 per pen as more competitors enter Canada's market.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spending is unlikely to decline even as a semaglutide generic is expected mid-2026.
CDA Draft: Cover Mounjaro With 25-49% Discount at Higher Doses
Canada's Drug Agency draft report recommends public plans cover Mounjaro for Type 2 diabetes if Eli Lilly grants 25-49% discounts at higher dosages.
Ozempic Tops Canadian Public Drug Spending at $807M: CIHI
Ozempic accounted for $807 million of the $20.1 billion spent on public drug plans across Canada, according to CIHI data released in March 2026.
Health Canada Pausing Generic Semaglutide Reviews, Spokesperson Confirms
Health Canada confirms it pauses generic semaglutide reviews when data is missing, with the clock stopping while manufacturers respond to information requests.
Pharmacy Expert Projects $100/Month Generic Semaglutide in Canada
University of Toronto pharmacy expert Mina Tadrous estimates Canadian generic semaglutide could land near $100 monthly once enough approved versions reach pharmacies.
Endoscopic Procedure Shows Promise for Patients Stopping Tirzepatide
Interim trial data show duodenal mucosal resurfacing helped tirzepatide patients retain over 80% of weight loss after stopping the drug, Reuters reports.
Sandoz CEO Calls Canada World's Second-Largest GLP-1 Market
Sandoz CEO Richard Saynor describes Canada as the world's second-largest GLP-1 market, raising cross-border supply concerns as generics near approval.
TrumpRx GLP-1 Deal Unlikely to Lower Canadian Prices, Experts Say
US TrumpRx program starts GLP-1 prices at US$350, dropping to US$245 over two years, but Canadian prices are already lower and generics loom.
Quebec Public Insurance Declines to Cover Wegovy, Citing Cost
Quebec's health research institute says Wegovy's cost is too high and benefits uncertain, keeping the Novo Nordisk semaglutide pen off the province's public formulary.
Canadians Battle Insurers for Semaglutide Coverage Amid Generic Delay
CTV News reports Canadians are still fighting insurers to cover Ozempic as generic semaglutide remains unapproved more than three months after patent expiry.
Apotex Has Three Separate Generic Semaglutide Filings in Canada
Apotex has filed three separate generic semaglutide applications with Health Canada in January, April and November 2025, the Globe and Mail reports.
Oldest Generic Semaglutide Filing Dates to February 2024
Health Canada's generic semaglutide queue includes applications filed as early as February 2024, with nine submissions pending and Apotex holding three 2025 filings.
Sandoz Eyes End-of-June Canadian Launch for Unbranded Semaglutide
Sandoz told Reuters unbranded Ozempic could launch in Canada by end of June, as generic semaglutide rolls out across India, China, Brazil and Turkey.
Canadian Patients, Doctors Frustrated by Generic Semaglutide Delay
Over three months after Canada's semaglutide patent expired, none of the nine generic applications at Health Canada have been approved, frustrating patients.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada